Yamamoto Kazuhiro, Matsuyama Satoru, Sonoda Keita, Murakami Souichirou, Mori Naoki, Higaki Kensaku, Nasu Kenji, Kikuno Motoyuki
Dept. of Surgery, Medical Corporation Kouhoukai Takagi Hospital.
Gan To Kagaku Ryoho. 2010 Feb;37(2):343-6.
A 73-year-old woman was admitted to our hospital for hemorrhagic shock due to HCC rupture and treated by transcatheter arterial chemoembolization (TACE) in July 2007, followed by partial hepatic resection two months later. Multiple pulmonary and remnant liver metastases were detected by CT six months after the surgery. Since treatment with UFT for two months was not effective, the chemotherapy was changed to S-1 100 mg/body/day in June 2008. After S-1 treatment for three months, lung metastases remarkably diminished, as did the serum AFP level. Meanwhile, although the S-1 dose was gradually reduced to 50 mg/body/day due to adverse effects, pulmonary lesions and serum AFP level remained stationary for five months. While there is no established regimen for distant metastases of HCC, S-1 may be effective even at a reduced dose.
一名73岁女性因肝癌破裂导致出血性休克于2007年7月入住我院，接受了经导管动脉化疗栓塞术（TACE）治疗，两个月后进行了部分肝切除术。术后6个月通过CT检测到多发肺转移和残余肝转移。由于使用优福定治疗两个月无效，2008年6月将化疗方案改为S-1，每日100毫克/体。使用S-1治疗三个月后，肺转移灶明显缩小，血清甲胎蛋白水平也下降。同时，尽管因不良反应S-1剂量逐渐减至每日50毫克/体，但肺部病变和血清甲胎蛋白水平在五个月内保持稳定。虽然尚无针对肝癌远处转移的确立方案，但S-1即使在减量情况下可能也有效。
